全文获取类型
收费全文 | 2370篇 |
免费 | 201篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 32篇 |
妇产科学 | 7篇 |
基础医学 | 293篇 |
口腔科学 | 21篇 |
临床医学 | 147篇 |
内科学 | 796篇 |
皮肤病学 | 38篇 |
神经病学 | 139篇 |
特种医学 | 49篇 |
外科学 | 540篇 |
综合类 | 9篇 |
预防医学 | 58篇 |
眼科学 | 19篇 |
药学 | 105篇 |
中国医学 | 3篇 |
肿瘤学 | 321篇 |
出版年
2024年 | 3篇 |
2023年 | 26篇 |
2022年 | 71篇 |
2021年 | 105篇 |
2020年 | 66篇 |
2019年 | 76篇 |
2018年 | 87篇 |
2017年 | 93篇 |
2016年 | 92篇 |
2015年 | 93篇 |
2014年 | 93篇 |
2013年 | 109篇 |
2012年 | 180篇 |
2011年 | 205篇 |
2010年 | 113篇 |
2009年 | 102篇 |
2008年 | 133篇 |
2007年 | 138篇 |
2006年 | 144篇 |
2005年 | 125篇 |
2004年 | 117篇 |
2003年 | 99篇 |
2002年 | 117篇 |
2001年 | 33篇 |
2000年 | 24篇 |
1999年 | 17篇 |
1998年 | 27篇 |
1997年 | 13篇 |
1996年 | 7篇 |
1995年 | 13篇 |
1994年 | 4篇 |
1993年 | 3篇 |
1992年 | 7篇 |
1991年 | 9篇 |
1989年 | 3篇 |
1988年 | 4篇 |
1987年 | 2篇 |
1986年 | 3篇 |
1985年 | 8篇 |
1984年 | 3篇 |
1983年 | 4篇 |
1982年 | 3篇 |
1980年 | 1篇 |
1978年 | 4篇 |
1977年 | 2篇 |
1974年 | 2篇 |
1973年 | 2篇 |
1972年 | 1篇 |
1965年 | 1篇 |
排序方式: 共有2587条查询结果,搜索用时 15 毫秒
21.
22.
23.
24.
Daisuke Miyaki Hiroshi Aikata Hiromi Kan Hatsue Fujino Ayako Urabe Keiichi Masaki Takayuki Fukuhara Tomoki Kobayashi Noriaki Naeshiro Takashi Nakahara Tomokazu Kawaoka Akira Hiramatsu Shoichi Takahashi Masaki Ishikawa Hideaki Kakizawa Kazuo Awai Kazuaki Chayama 《Journal of gastroenterology and hepatology》2013,28(12):1834-1841
25.
Tomoki Kobayashi Hiroshi Aikata Tsuyoshi Kobayashi Hideki Ohdan Koji Arihiro Kazuaki Chayama 《Hepatobiliary & pancreatic diseases international : HBPD INT》2017,16(3):279-288
BACKGROUND: Early recurrence(ER) after hepatic resection(HR) is a poor prognostic factor for patients with hepatocellular carcinoma(HCC). This study aimed to identify the clinicopathological features, outcomes, and risk factors for ER after HR for small HCC in order to clarify the reasons why ER is a worse recurrence pattern.METHODS: We retrospectively examined 130 patients who underwent HR for small HCC(≤30 mm). Recurrence was classified into ER(2 years) and late recurrence(LR)(≥2 years). The clinicopathological features, outcomes, and risk factors for ER were analyzed by multivariate analysis.RESULTS: ER was observed in 39 patients(30.0%). The survival rate of the ER group was significantly lower than that of the LR group(P0.005), and ER was an independent prognostic factor for poor survival(P=0.0001). The ER group had a significantly higher frequency(P=0.0039) and shorter interval(P=0.027) of development to carcinoma beyond the Milan criteria(DBMC) compared with the LR group, and ER was an independent risk factor for DBMC(P0.0001). Multi-nodularity, non-simple nodular type, and microvascular invasion were independent predictors for ER(P=0.012, 0.010, and 0.019, respectively).CONCLUSIONS: ER was a highly malignant recurrence pattern associated with DBMC and subsequent poor survival after HR for small HCC. Multi-nodularity, non-simple nodular type, and microvascular invasion predict ER, and taking these factors into consideration may be useful for the decision of the treatment strategy for small HCC after HR. 相似文献
26.
27.
28.
Yukihiro Yokoyama Masato Nagino Hideki Nishio Tomoki Ebata Tsuyoshi Igami Yuji Nimura 《Journal of hepato-biliary-pancreatic sciences》2007,14(5):447-454
The clinical application of portal vein embolization (PVE) has contributed to improving the postoperative outcome of hilar cholangiocarcinoma. The enlarged nonembolized lobe after PVE protects the patient from postoperative hepatic failure, due to the increased functional reserve, and shortens the hospital stay. Although numerous reports have shown beneficial effects of PVE on postoperative outcome after extended hepatectomy, no randomized controlled study has been performed so far. It is urgent to establish a “gold standard” of PVE, because the indications, approach to the portal vein, types of embolic materials, and methods used to evaluate the function of the future liver remnant are variable among institutions. The indications and procedures of PVE for hilar cholangiocarcinoma may be different from those for hepatocellular carcinoma or colorectal metastasis, because, in many patients with hilar cholangiocarcinoma, biliary cancer is associated with biliary obstruction and cholangitis. This review article summarizes the contribution of PVE to the outcome of postoperative management in patients with hilar cholangiocarcinoma needing extended hepatectomy. We also describe our PVE procedure, which has been established from our experience of more than 240 cases of biliary cancer. Furthermore, the drawbacks of PVE, which may reduce the pool of candidates for surgery, are also discussed. 相似文献
29.
Tanaka S Nishigaki K Ojio S Okubo M Yasuda S Ishihara Y Kubota T Takasugi N Kawamura I Yamaki T Ushikoshi H Aoyama T Kawasaki M Takemura G Minatoguchi S 《Journal of cardiology》2008,52(1):39-48
BACKGROUND: Aspirin and anti-platelet drugs are used commonly for patients with coronary heart disease. Proton pump inhibitor (PPI) and high-dose H2-blocker were recommended for preventing NSAIDs-related ulcer. Previously H2-blocker reported to have some negative cardiovascular effects. Additionally, a recent in vitro study showed that PPI reduced cardiac contractility. In this study, we evaluated whether chronic administration of PPI and high-dose H2-blocker affects left ventricular function. METHOD: Fifty-two stable angina patients were enrolled and classified into PPI group ([P]; lansoprazole: 15mg/day, n=28), H2-blocker group ([H]; famotidine: 40mg/day, n=8), and control ([C]; none or mucosal-defense drug, n=16). Eligible patients showed normal cardiac function in initial catheterization without administrated PPI or H2-blocker. They received percutaneous coronary intervention and follow-up catheterization. We compared changes in ejection fraction (EF: %), end diastolic/systolic volume index (EDVI/ESVI: ml/m(2)), and peak positive/negative dp/dt (+/-dp/dt: mmHg/s) in left ventricular angiography series. RESULT: There were no significant differences among three groups regarding patient characteristics, backgrounds of angiographic and intervention, except for fewer smokers in [C]. Other drugs such as beta- and Ca-blocker did not have effects on cardiac function except for aspirin during 255+/-115 days follow-up. Rate of EF changes significantly decreased in [P], and tended to decrease in [H] (C: 3.8+/-9.8%, H: -1.6+/-7.6%, P: -2.1+/-5.9%; p<0.05 for [C] vs. [P]). Those of ESVI changes were significantly greater in [P], and tended to be greater in [H] (C: -4.5+/-16.2%, H: 4.9+/-15.5%, P: 7.3+/-16.2%; p<0.05 for [C] vs. [P]), though, EDVI changes' were similar (C: 2.5+/-8.9%, H: 2.6+/-3.6%, P: 1.6+/-6.1%; p=ns). Rate of +/-dp/dt-changes tended to decrease in [H] (+dp/dt: C: 3.9+/-15.5%, H: -10.0+/-25.2%, P: 0.3+/-19.6%; p=ns, -dp/dt: C: -0.1+/-19.5%, H: -8.5+/-20.4%, P: 5.7+/-27.7%; p=ns). CONCLUSION: In this study, PPI and high-dose H2-blocker have EF-reducing tendency. However, these changes were small and these drugs seemed to exhibit little influence clinically. 相似文献
30.
In vivo expression patterns of survivin and its splicing variants in chronic liver disease and hepatocellular carcinoma. 总被引:12,自引:0,他引:12